Trial Profile
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TANGOKIDS
- Sponsors Melinta Therapeutics; Rempex Pharmaceuticals
- 26 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2025.
- 26 Sep 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2024.
- 10 Jan 2023 Planned number of patients changed from 60 to 67.